CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 62 filers reported holding CRISPR THERAPEUTICS AG in Q3 2017. The put-call ratio across all filers is 1.87 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $12,705,000 | -35.6% | 444,708 | 0.0% | 3.49% | -2.8% |
| Q3 2018 | $19,723,000 | -24.5% | 444,708 | 0.0% | 3.59% | -43.1% |
| Q2 2018 | $26,131,000 | -4.0% | 444,708 | -25.3% | 6.31% | -57.1% |
| Q1 2018 | $27,227,000 | +128.4% | 595,642 | +17.3% | 14.70% | +163.7% |
| Q4 2017 | $11,922,000 | +26.4% | 507,730 | -3.8% | 5.58% | +27.4% |
| Q3 2017 | $9,431,000 | +11.6% | 527,730 | 0.0% | 4.38% | -26.3% |
| Q2 2017 | $8,454,000 | -33.8% | 527,730 | -10.0% | 5.94% | -9.2% |
| Q1 2017 | $12,767,000 | +7.4% | 586,475 | 0.0% | 6.54% | -23.1% |
| Q4 2016 | $11,882,000 | – | 586,475 | – | 8.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |